INTERPACE BIOSCIENCES, INC. (IDXG)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 60M 120M 180M FY10: 134.6M FY11: 157.3M FY12: 126.9M FY13: 146.5M FY14: 119.9M FY15: 9.4M FY16: 13.1M FY17: 15.9M FY18: 21.9M FY19: 24.2M FY20: 32.4M FY21: 33.1M FY22: 31.8M FY23: 40M FY24: 46.9M FY25: 38.7M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 15M 30M 45M FY10: 26.6M FY11: 32.5M FY12: 26.9M FY13: 23.5M FY14: 206K FY15: 2.5M FY16: 6.4M FY17: 8.5M FY18: 11.7M FY19: 8.3M FY20: 10.7M FY21: 18.8M FY22: 18.2M FY23: 25.1M FY24: 29.9M FY25: 24.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY10: -6.9M FY11: -4.7M FY12: -25.2M FY13: -1.4M FY14: -17.8M FY15: -40.4M FY16: -6.4M FY17: -6.3M FY18: -12.6M FY19: -26.4M FY20: -26.1M FY21: -6.3M FY22: -3.6M FY23: 4M FY24: 8.1M FY25: 4.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-30M -20M -10M 0 10M 20M 30M FY10: -6.8M FY11: -11.9M FY12: -25.5M FY13: -4.6M FY14: -16.8M FY15: -13.6M FY16: -22M FY17: 12.6M FY18: -12.7M FY19: -26.7M FY20: -26.5M FY21: -14.9M FY22: -22M FY23: 2M FY24: 6.7M FY25: 24.6M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 8M 16M 24M FY14: 1.3M FY15: 6.9M FY16: 6.6M FY17: 7.4M FY18: 10.2M FY19: 15.9M FY20: 21.7M FY21: 14.3M FY22: 13.6M FY23: 15M FY24: 17M FY25: 14.6M FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY10: 16.4M FY11: 2M FY12: -10.3M FY13: -3.5M FY14: -16.4M FY15: -19.8M FY16: -7.6M FY17: -15.3M FY18: -8.7M FY19: -19M FY20: -14M FY21: -8.7M FY22: -7.7M FY23: 3.8M FY24: 4.6M FY25: 5.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-21M -14M -7M 0 7M 14M 21M FY10: 14.2M FY11: 1.6M FY12: -11.4M FY13: -5.3M FY14: -19.2M FY15: -20.2M FY17: -15.3M FY18: -9.1M FY19: -19.1M FY20: -15.6M FY21: -9.1M FY22: -8M FY23: 3.3M FY24: 3.8M FY25: 5.5M FY10 FY12 FY14 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 10M 20M 30M FY10: 14.3M FY11: 14.4M FY12: 14.6M FY13: 14.7M FY14: 14.9M FY15: 1.5M FY16: 1.8M FY17: 15.8M FY18: 2.8M FY19: 3.7M FY20: 4M FY21: 4.1M FY22: 4.2M FY23: 4.4M FY24: 15.7M FY25: 27.7M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-150.00 -100.00 -50.00 0.00 50.00 100.00 150.00 Q4 '10: -0.48 Q1 '11: -0.39 Q2 '11: -0.39 Q3 '11: -0.29 Q4 '11: -0.83 Q1 '12: -0.81 Q2 '12: -0.78 Q3 '12: -0.84 Q4 '12: -1.75 Q1 '13: -1.59 Q2 '13: -1.62 Q3 '13: -1.70 Q4 '13: -0.32 Q1 '14: -0.57 Q2 '14: -0.69 Q3 '14: -0.83 Q4 '15: -87.95 Q1 '16: -90.38 Q2 '16: -91.21 Q3 '16: -95.03 Q4 '16: -120.91 Q1 '17: -117.67 Q2 '17: -117.03 Q3 '17: -113.05 Q4 '17: -7.61 Q1 '18: -8.27 Q2 '18: -7.69 Q3 '20: -8.20 Q4 '20: -7.32 Q1 '21: -5.97 Q2 '21: -5.43 Q3 '21: -4.74 Q4 '21: -3.61 Q1 '22: -3.11 Q2 '22: -3.20 Q3 '22: -5.70 Q4 '22: -5.17 Q1 '23: -4.56 Q2 '23: -3.59 Q3 '23: -0.38 Q4 '23: 0.23 Q1 '24: 0.31 Q2 '24: 0.82 Q3 '24: 1.34 Q4 '24: 1.41 Q1 '25: 1.31 Q2 '25: 0.62 Q3 '25: 0.27 Q4 '25: 0.77 Q1 '26: 0.74 Q2 '26: 0.89 Q1 '11 Q4 '12 Q3 '14 Q2 '17 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.